Effect of the RET Inhibitor Vandetanib in a Patient With RET Fusion-Positive Metastatic Non-Small-Cell Lung Cancer

J Clin Oncol. 2016 May 20;34(15):e141-4. doi: 10.1200/JCO.2013.50.5016. Epub 2014 Nov 3.

Authors

Gerald S Falchook¹, Nelson G Ordóñez², Christel C Bastida², Philip J Stephens³, Vincent A Miller³, Lindsay Gaido², Tiffiny Jackson², Daniel D Karp²

Affiliations

¹ The University of Texas MD Anderson Cancer Center, Houston, TX Gerald.Falchook@scresearch.net.
² The University of Texas MD Anderson Cancer Center, Houston, TX.
³ Foundation Medicine, Cambridge, MA.

PMID: 25366691
DOI: 10.1200/JCO.2013.50.5016

No abstract available

Publication types

Case Reports

MeSH terms

Adult
Carcinoma, Non-Small-Cell Lung / drug therapy*
Carcinoma, Non-Small-Cell Lung / metabolism
Carcinoma, Non-Small-Cell Lung / pathology
Cytoskeletal Proteins / antagonists & inhibitors
Cytoskeletal Proteins / metabolism
Female
Humans
Lung Neoplasms / drug therapy*
Lung Neoplasms / metabolism
Lung Neoplasms / pathology
Neoplasm Metastasis
Oncogene Proteins, Fusion / antagonists & inhibitors
Oncogene Proteins, Fusion / metabolism
Piperidines / therapeutic use*
Proto-Oncogene Proteins c-ret / antagonists & inhibitors*
Proto-Oncogene Proteins c-ret / metabolism
Quinazolines / therapeutic use*
Treatment Outcome

Substances

CCDC6 protein, human
Cytoskeletal Proteins
Oncogene Proteins, Fusion
Piperidines
Quinazolines
Proto-Oncogene Proteins c-ret
vandetanib